This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentation has concluded.

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentation has concluded.

ProMIS Neurosciences, Inc. , a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show ...

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Artificial intelligence has reshaped nearly every industry, but drug discovery has always been its toughest proving ground. Molecules don't follow ...

Danaher Corporation DHR is scheduled to release third-quarter 2025 results on Oct. 21, before market open. The Zacks Consensus Estimate for revenues is pegged at $6.00 billion, which indicates an ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives ...

An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...

Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...